LongBio Pharma是一家位于中国上海的生物科技公司。该公司成立于2018年，专注于自身免疫性和罕见疾病，服务于患者和社会。
LongBio Pharma的联合创始人，孙博士，Bill， Nai-chau，也是Tanox的联合创始人，2000年在纳斯达克首次公开募股，2007年被基因泰克收购。他也是美国食品和药物管理局批准的第一种抗IgE抗体Omalizumab（Xolair®，2022年全球销售额3.6B美元）的共同发明者。
目标是与合作伙伴合作，将我们的药物推向国内和国际市场，特别是为患者带来更实惠、高质量的生物药物。
我们的领先管道是下一代抗IgE抗体（LP-003），它已经在第三阶段研究，并为2025年的BLA做准备。第二个领先管道是双功能补体抑制剂（LP-005），目前处于第二阶段，打算在2025H1开始第三阶段。
Dr Sun, Bill Nai-chau co-founded Longbio in 2018. He is also a member of the Board at present.
Dr. Sun boasts a distinguished career as a serial entrepreneur, marked by numerous successes. Notably, he co-founded Tanox Inc. in 1986 and led its R&D department. Tanox, a biotech company based in Houston, US, went public on Nasdaq in 2000. In a significant milestone, the company was acquired by Genentech in 2006 for a staggering sum of 919 million USD. During his tenure at Tanox, Dr. Sun served as the main inventor behind the groundbreaking first-generation anti-IgE antibody, Omalizumab (marketed as Xolair®), which emerged as a blockbuster in asthma and allergic diseases. Since its listing over two decades ago, Omalizumab has amassed cumulative sales revenue exceeding 30 billion USD, with annual revenues still surpassing 3.5 billion USD. Prior to his involvement with Longbio, Dr. Sun held the position of Founder and President at Xuhua, a drug discovery company in China, starting from 2001. Under his leadership, Xuhua collaborated on several innovative drug projects with listed companies in China, including the successful approval of Benegrastim (marketed as Ryzneuta®) by the US FDA and China NMPA in 2023. Dr. Sun's early career included research roles at Oak Ridge National Laboratory and the National Cancer Institute. He earned his Ph.D. from Iowa State University.
Dr Sun, Bill Nai-chau co-founded Longbio in 2018. He is also a member of the Board at present.
Dr. Sun boasts a distinguished career as a serial entrepreneur, marked by numerous successes. Notably, he co-founded Tanox Inc. in 1986 and led its R&D department. Tanox, a biotech company based in Houston, US, went public on Nasdaq in 2000. In a significant milestone, the company was acquired by Genentech in 2006 for a staggering sum of 919 million USD. During his tenure at Tanox, Dr. Sun served as the main inventor behind the groundbreaking first-generation anti-IgE antibody, Omalizumab (marketed as Xolair®), which emerged as a blockbuster in asthma and allergic diseases. Since its listing over two decades ago, Omalizumab has amassed cumulative sales revenue exceeding 30 billion USD, with annual revenues still surpassing 3.5 billion USD. Prior to his involvement with Longbio, Dr. Sun held the position of Founder and President at Xuhua, a drug discovery company in China, starting from 2001. Under his leadership, Xuhua collaborated on several innovative drug projects with listed companies in China, including the successful approval of Benegrastim (marketed as Ryzneuta®) by the US FDA and China NMPA in 2023. Dr. Sun's early career included research roles at Oak Ridge National Laboratory and the National Cancer Institute. He earned his Ph.D. from Iowa State University.
Dr Sun, Bill Nai-chau co-founded Longbio in 2018. He is also a member of the Board at present.
Dr. Sun boasts a distinguished career as a serial entrepreneur, marked by numerous successes. Notably, he co-founded Tanox Inc. in 1986 and led its R&D department. Tanox, a biotech company based in Houston, US, went public on Nasdaq in 2000. In a significant milestone, the company was acquired by Genentech in 2006 for a staggering sum of 919 million USD. During his tenure at Tanox, Dr. Sun served as the main inventor behind the groundbreaking first-generation anti-IgE antibody, Omalizumab (marketed as Xolair®), which emerged as a blockbuster in asthma and allergic diseases. Since its listing over two decades ago, Omalizumab has amassed cumulative sales revenue exceeding 30 billion USD, with annual revenues still surpassing 3.5 billion USD. Prior to his involvement with Longbio, Dr. Sun held the position of Founder and President at Xuhua, a drug discovery company in China, starting from 2001. Under his leadership, Xuhua collaborated on several innovative drug projects with listed companies in China, including the successful approval of Benegrastim (marketed as Ryzneuta®) by the US FDA and China NMPA in 2023. Dr. Sun's early career included research roles at Oak Ridge National Laboratory and the National Cancer Institute. He earned his Ph.D. from Iowa State University.